Recently, PSMA has been identified as a potential diagnostic and therapeutic target in ACCs because it is highly expressed in carcinomas (12, 13), and Zr89-J591 WB-PET-CT was reported to be useful for detecting metastases. Here, FOLH1 is linked to carcinoma.